Becton, Dickenson buys TVA Medical for its access technology

Pursuing newly FDA-approved vascular access technology for patients on dialysis, Becton, Dickenson and Company has agreed to buy TVA Medical in an all-cash transaction. Terms of the sale were not disclosed.

With the acquisition, Becton, Dickenson and Company (BD) can offer the everlinQ endoAVF System, a new endovascular arteriovenous fistula technology developed by Teva Medical and approved by the FDA in June that adds to BD’s ESRD portfolio of dialysis catheters, drug-coated balloons, standard angioplasty balloons and endovascular stent graft products.

“The addition of TVA Medical allows BD to provide another innovative device to physicians who treat patients suffering from chronic kidney disease requiring hemodialysis,” said Steve Williamson, worldwide president of peripheral intervention at BD, in a company press release. “This technology is highly complementary to our peripheral intervention offerings, and we will continue to bring new technologies to market that improve our category-leading ESRD portfolio. This is a great example of our continued strategy to use tuck-in acquisitions to advance category leadership.”

According to a company press release, the everlinQ endoAVF System uses two, thin, flexible, magnetic catheters that are inserted into the ulnar artery and the ulnar vein in the arm through a small puncture. When placed close to each other, the magnets in each catheter attract, pulling the vessels together. After confirming alignment, an electrode from the venous catheter delivers radiofrequency energy to create the connection between the artery and vein. The fistula is confirmed with an angiogram to show that arterial blood is flowing to the low-pressure venous system. The procedure minimizes the amount of vessel and skin trauma compared to traditional fistula creation using open surgery, the company said.

“BD will enable us to deliver to physicians and patients what we believe is a highly desirable and transformative endovascular technology as an integral part of a broader ESRD-focused portfolio of solutions,” said Adam L. Berman, co-founder of TVA Medical.

The device is commercially available in Europe and Canada. The product name will be transitioned to WavelinQ EndoAVF System during integration, the company said.

 

 

Reference:

http://investors.bd.com/phoenix.zhtml?c=64106&p=irol-newsArticle&ID=2357325

Pursuing newly FDA-approved vascular access technology for patients on dialysis, Becton, Dickenson and Company has agreed to buy TVA Medical in an all-cash transaction. Terms of the sale were not disclosed.

With the acquisition, Becton, Dickenson and Company (BD) can offer the everlinQ endoAVF System, a new endovascular arteriovenous fistula technology developed by Teva Medical and approved by the FDA in June that adds to BD’s ESRD portfolio of dialysis catheters, drug-coated balloons, standard angioplasty balloons and endovascular stent graft products.

“The addition of TVA Medical allows BD to provide another innovative device to physicians who treat patients suffering from chronic kidney disease requiring hemodialysis,” said Steve Williamson, worldwide president of peripheral intervention at BD, in a company press release. “This technology is highly complementary to our peripheral intervention offerings, and we will continue to bring new technologies to market that improve our category-leading ESRD portfolio. This is a great example of our continued strategy to use tuck-in acquisitions to advance category leadership.”

According to a company press release, the everlinQ endoAVF System uses two, thin, flexible, magnetic catheters that are inserted into the ulnar artery and the ulnar vein in the arm through a small puncture. When placed close to each other, the magnets in each catheter attract, pulling the vessels together. After confirming alignment, an electrode from the venous catheter delivers radiofrequency energy to create the connection between the artery and vein. The fistula is confirmed with an angiogram to show that arterial blood is flowing to the low-pressure venous system. The procedure minimizes the amount of vessel and skin trauma compared to traditional fistula creation using open surgery, the company said.

“BD will enable us to deliver to physicians and patients what we believe is a highly desirable and transformative endovascular technology as an integral part of a broader ESRD-focused portfolio of solutions,” said Adam L. Berman, co-founder of TVA Medical.

The device is commercially available in Europe and Canada. The product name will be transitioned to WavelinQ EndoAVF System during integration, the company said.

 

 

Reference:

http://investors.bd.com/phoenix.zhtml?c=64106&p=irol-newsArticle&ID=2357325